A Study of FCN-338 in Patients With Chronic CLL/SLL

Summary

This study is being done to evaluate the Tolerability、Pharmacokinetics and Preliminary antitumor activity of oral FCN-338 for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have failed or are intolerant to one or more lines of established therapy or for whom no other treatment options are available.

Timeline

Start

2021-05-13

Primary completion

2024-04-28

Completion

2024-12-31

Drugs

Indications